Inhibitory effect of dimethylthiourea on rat urinary bladder inflammation produced by 6-hydroxydopamine application.
The present study was to investigate 6-hydroxydopamine (6-OHDA)-induced inflammatory response and underlying mechanisms in the urinary bladder in anesthetized male rats of Long-Evans strain. The magnitude of inflammation was evaluated by morphometric analysis of the relative number of leaky blood vessels expressed by the area density of India ink-labeled blood vessels in whole mount specimens. Light and scanning electron microscopies were employed to study the changes in histologic structure and endothelial ultrastructure of bladder wall. Local injection of 6-OHDA to lumen of urinary bladder induced a dose-dependent increase in plasma leakage. Following application of vehicle, 5 mg/kg 6-OHDA, and 10 mg/kg 6-OHDA, area densities of India ink-labeled leaky vessels were 5.65+/-3.72% (N=6), 22.63+/-5.12% (N=6), and 35.02+/-11.25% (N=6), respectively. Inflammatory response was completely abolished by pretreatment alone with dimethylthiourea (DMTU), a hydroxyl radical scavenger, and was also attenuated by pretreatment with L-732,138, a NK1 receptor antagonist. 6-OHDA caused edema formation and venular endothelial gap formation in bladder tissue. It is concluded that 6-OHDA induced inflammation in the rat urinary bladder, the response of which was dose-dependently increased and free radicals and tachykinins were involved in the inflammatory process.
Huang
Wen-Hung
WH
Department of Biological Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan.
Chang
Wei-Ban
WB
Liu
Shang-Pin
SP
Lin
Jen-Tai
JT
Fu
Yaw-Syan
YS
Chang
Min-Chi
MC
Huang
Hung-Tu
HT
D000818:Animals; D019559:Capillary Leak Syndrome / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control; D002199:Capillary Permeability / Q000187:drug effects / Q000502:physiology; D003556:Cystitis / Q000139:chemically induced* / Q000378:metabolism / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D007249:Inflammation / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control; D008297:Male; D016627:Oxidopamine / Q000037:antagonists & inhibitors / Q000633:toxicity*; D051381:Rats; D020318:Rats, Long-Evans; D013890:Thiourea / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001743:Urinary Bladder / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*
D016627:Oxidopamine; C038983:1,3-dimethylthiourea; D013890:Thiourea